LOGIN  |  REGISTER

Crinetics Pharmaceuticals (NASDAQ: CRNX) Stock Quote

Last Trade: US$44.59 -3.44 -7.16
Volume: 1,109,017
5-Day Change: -4.42%
YTD Change: 25.32%
Market Cap: US$3.470B

Latest News From Crinetics Pharmaceuticals

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the... Read More
56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Management Will Host a Conference Call Today at 8:30 a.m. Eastern Time SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage... Read More
Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positive Data Previously Reported Management to Host a Conference Call Today at 4:30 p.m. Eastern Time SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics... Read More
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the... Read More
Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024 Announced a $350 Million Private Placement Equity Financing Management Hosting Conference Call and Webcast at 4:30 p.m. ET Today SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.... Read More
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select... Read More
SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast... Read More
SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan... Read More
SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan... Read More
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D. , founder and chief executive officer of Crinetics, will present at the 42 nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024. Details of the corporate presentation are as follows: Date: Tuesday, January 9, 2024 Time: 3:45 p.m.... Read More
Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies Phase 2 Study Enrollment is Complete (N=36), and Topline Results Expected in 1H 2024 Management to Host a Conference Call Today at 5:00 p.m. Eastern Time SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics... Read More
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on December 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to... Read More
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6 th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35 th Annual Healthcare Conference in New York City. Details of the fireside chats are as follows: 6 th Annual Evercore ISI HealthCONx Conference: Date: Tuesday,... Read More
SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on November 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to... Read More
Phase 3 PATHFNDR-1 Study Met Primary and All Secondary Endpoints as Reported in September Phase 3 PATHFNDR-2 Study Topline Data Expected in 1Q 2024 Initial Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome Expected in December 2023 SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2023. “The... Read More
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on October 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase... Read More
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023. Details of the fireside chat are as follows: Date: Tuesday, September 26, 2023 Time: 1:00 p.m. Eastern Time The live and... Read More
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 11,441,648 shares of its common stock at a price to the public of $30.59 per share.... Read More
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten... Read More
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on September 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to... Read More
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from Injected Depot Standard of Care Mean Acromegaly Symptom Diary Scores Were Maintained on Paltusotine vs. an Increase on Placebo (p=0.02) After Switching from Injected Depot Standard of Care Paltusotine Was Well-Tolerated with No... Read More
SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on August 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase... Read More
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 CRN04777 Development Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30,... Read More
SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the... Read More
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on July 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an... Read More
Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics' Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from ENDO President SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented efficacy, safety and patient-reported outcome (PRO) data at ENDO 2023 for paltusotine, an experimental, once-daily,... Read More
SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on June 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an... Read More
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois. Two presentations will provide additional clinical evidence and patient-reported data for paltusotine , an experimental, once-daily, oral,... Read More
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on May 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an... Read More
Phase 3 PATHFNDR-1 study topline data expected in 3Q 2023 Phase 3 PATHFNDR-2 study topline data expected in 1Q 2024 and enrollment target increased to up to 98 per prespecified protocol criteria Paltusotine’s Phase 2 study in carcinoid syndrome on track for preliminary data in 4Q 2023 SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the first... Read More
SAN DIEGO, April 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on April 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase... Read More
SAN DIEGO, March 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on March 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase... Read More
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024 Paltusotine’s Phase 2 study in carcinoid syndrome on track for data in 2H 2023 CRN04894’s studies in Cushing’s disease and... Read More
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on February 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to... Read More
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023. Details of the presentation are as follows: Date: Tuesday, February 14, 2023 Time: 3:40 p.m. Eastern Time The live and archived webcast will be... Read More
SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on January 9, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase... Read More
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of paltusotine in carcinoid syndrome on track for topline data in 2H 2023 Clinical trials of CRN04894 in ACTH-dependent Cushing’s Syndrome and Congenital Adrenal Hyperplasia expected to begin in 1Q 2023 SAN DIEGO, Jan. 09, 2023 (GLOBE... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB